A successful re-trial after clozapine myopericarditis
Abstract
a 29-year-old man with a history of schizophrenia presented to our emergency department with acute psychosis manifesting as visual and auditory hallucinations associated with paranoid delusions and persecutory thoughts. he had been on treatment with monthly paliperidone 100 mg depot and had had recurrent lengthy admissions for previous episodes of psychosis. he had a history of polysubstance abuse and smoking. Clinical examination was normal apart from the mental state examination which was consistent with a relapse of schizophrenia, with a high risk of aggression and misadventure.
he was commenced on clozapine with monitoring as per local protocol. on day 16 of treatment he developed fever and tachycardia and shortly afterwards reported chest pain. his clinical examination remained unchanged; however, routine investigations revealed elevated troponin i, raised C-reactive protein (CrP) (figure 1) and 12-lead eCg revealed dynamic t-Wave inversion in v5-v6 and leads i and avl. Clozapine was discontinued and the patient was transferred to the Coronary Care unit for management of presumed clozapineinduced myopericarditis. a Ct coronary angiogram showed a calcium score of 0 with no signifi cant coronary disease. transthoracic echocardiography (tte) revealed normal left ventricular size and function, no signifi cant valvular pathology and no pericardial effusion. inflammatory markers and cardiac enzymes were monitored until all had normalised. in the interim, the patient was managed with alternative antipsychotics. he required multiple lengthy admissions due to poorly controlled schizophrenia over the next two years, refl ecting the relative effi cacy of clozapine in this setting.
baseline investigations including eCg, tte, troponin, CKmb, brain natriuretic peptide, full blood count, erythrocyte sedimentation rate, and CrP were repeated. a protocol for monitoring was implemented that included daily clinical assessment, eCg and blood tests for the fi rst two weeks, with a fortnightly tte. Consent was obtained after explaining the risks and benefi ts to both the patient and family. Clozapine was commenced at a dose of 6.25 mg and increased in increments of 6.25 mg every week for the fi rst four weeks. following this, the dose was increased in increments of 12.5 mg weekly until a target dose of 300 mg was reached with adequate clinical effect. at two weeks of re-trial, frequency of blood tests was reduced to twice weekly; at four weeks this was reduced to weekly. at this time, monthly tte was implemented. the patient remained an inpatient in the psychiatry ward for the fi rst three months with ongoing monthly cardiology follow up for the next four months after discharge. the rationale behind the design of our monitoring regime and dose titration was based on published data suggesting a peak incidence of myopericarditis at two to three weeks after initiation of clozapine. 2 Cardiac mri was not available in our regional centre but would otherwise have been utilised as an adjunct in diagnosis.
at six months after commencement of the re-challenge, there has been no clinical, biochemical, or echocardiographic evidence of recurrent myopericarditis.
Clozapine is an atypical antipsychotic, specifi cally a tricyclic dibenzodiazepine. it is a highly effi cacious treatment in refractory schizophrenia; indeed it has been shown to reduce mortality in schizophrenia via a reduction in suicide. 3 however, its use is limited by a side effect profi le that includes cardiotoxicity. Clozapine myopericarditis was fi rst described over 15 years ago and has an incidence of approximately 1%. Email: kiran.sarathy@unsw.edu.au a number of possible pathophysiological mechanisms has been proposed including an ige-mediated hypersensitivity, a type 3 allergic reaction (though selective cardiac end organ damage makes this less likely), catecholamine-mediated ventricular dysfunction (akin to takostubo's cardiomyopathy) and a direct toxic effect on the heart with associated infl ammatory infi ltrate.
1 additionally, myopericarditis seems to exist on a spectrum of clozapine-related adverse drug reactions that ranges from tachycardia and pericarditis (without myocardial involvement) to severe cardiomyopathy and sudden cardiac death. it is worth noting that the incidence does not appear to be dose-dependent. 4 the natural history of this process typically involves a heart rate rise of 10-20 beats per minute within the fi rst 10-19 days after initiation of clozapine, though this may be unrelated to the development of myocarditis. after approximately day 20, the onset of generalised cardiorespiratory symptoms with an elevation of the CrP is generally noted with an associated worsening of the tachycardia. from about day 25 onwards, an elevation of the serum troponin (> 2 the upper limit of normal), the CrP (> 100 mg/l), and left ventricular impairment on echocardiography is seen. 5 our case highlights the feasibility of, and offers a protocol for, clozapine re-challenge, and adds to the limited number of published cases demonstrating that prior clozapine-induced myopericarditis is not an absolute contraindication to a rechallenge of clozapine treatment in selected cases. 
